Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy

Infez Med. 2018 Jun 1;26(2):160-163.

Abstract

A case of progressive multifocal leukoencephalopathy (PML) is described in an HIV-negative patient with mixed connective-tissue disease (MCTD) on a minimally immunosuppressive treatment with hydroxychloroquine. The patient presented with right-sided weakness, episodes of disorientation and loss of short-term memory and of vision in her right eye. PML was diagnosed by JCV DNA on cerebrospinal fluid and radiological criteria. She was treated with off-label maraviroc and mirtazapine but died two months after hospital admission, despite a surprising decrease in the viral load of cerebrospinal fluid three weeks after starting therapy. Prompt diagnosis and antiviral treatment of PML even in low-risk patients are warranted. Future studies are required to define the therapeutic role of maraviroc (MVC) and mirtazapine in this setting.

Publication types

  • Case Reports

MeSH terms

  • CCR5 Receptor Antagonists / administration & dosage*
  • Drug Therapy, Combination
  • Female
  • HIV Seronegativity
  • Humans
  • Leukoencephalopathy, Progressive Multifocal / drug therapy*
  • Maraviroc / administration & dosage*
  • Middle Aged
  • Mirtazapine / administration & dosage*

Substances

  • CCR5 Receptor Antagonists
  • Mirtazapine
  • Maraviroc